The purpose of this study is to identify what degree of symptom changes during the early weeks could be used to predict eventual nonresponse at week 6 among depressive inpatients taking fluoxetine.
Patients with major depressive disorder will receive 20 mg/day of fluoxetine for six weeks. Symptom severity was assessed by the 17-item Hamilton Depression Rating Scale (HAMD-17) at weeks 0, 1, 2, 3, 4 and 6. Stable response is defined as a reduction of 50% or more of the HAMD-17 score at week 4 and week 6 of treatment. Receiver operating characteristic curve will be used to determine the cutoff point of the percentage of HAMD-17 score reduction between stable responders and nonresponders at weeks 1, 2, 3 and 4.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
140
fluoxetine 20 mg/d
Kai-Suan Psychiatric Hospital
Kaohsiung City, Taiwan
Stable response was defined as a reduction of 50% or more of the HAMD-17 score at week 4 and week 6 of treatment
Time frame: 6 weeks after initiation of fluxetine
CGI, GAF, Zung's Depression Scale, Short-Form 36, auditory evoked potential, psychomotor speed
Time frame: 6 weeks after initiation of fluxetine
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.